8th Feb 2008 07:00
Sinclair Pharma plc notice of interim results
8th February 2008, Godalming, UK. Sinclair Pharma plc (SPH.L), the international specialty pharmaceutical company, announced today that it will release its Interim Financial Results for the period to 31 December 2007 on Wednesday, 27th February, 2008.
In conjunction with the financial results release there is an analyst presentation scheduled at 9am on Wednesday 27th February (UK time). This presentation will also be available live via conference call.
The presentation will be hosted by the Company's Chief Executive Officer, Dr Michael Flynn, and Chief Financial Officer, Jerry Randall.
Announcement: Sinclair Pharma plc Interim Financial ResultsDate: Wednesday 27th February, 2008Time: 09.00 (UK time)Location: Landsbanki Offices, London (by invitation only)
Conference call details are available on request, please contact Joanna Whineray at Capital MS&L [email protected].
- End -
For further information please contact:
Sinclair Pharma plc Tel: +44 (0)1483 410 600Dr Michael Flynn, CEOJerry Randall, CFOHalina Kukula, Investor Relations [email protected] MS&LAnna Mitchell / Joanna Whineray Tel +44 (0)20 7307 5346Notes to editors:Sinclair Pharma plc
Sinclair Pharma plc is an international specialty pharmaceutical company. It has a growing sales and marketing operation that is already present in France, Italy, UK, Spain and Portugal, and a complementary marketing partner network that spans more than 65 countries.
Sinclair has proven expertise in acquiring or developing commercially attractive and undervalued products, registering these products and bringing them to market within a short time frame. The company focuses on niche therapeutic areas and its current portfolio includes products for dermatological conditions and oral health.
In April 2007, Sinclair completed a dual listing on the Official List of the London Stock Exchange and Euronext Paris.
"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward- looking statements due to a variety of factors.
SINCLAIR PHARMA PLCRelated Shares:
Sinclair Pharma